Recenti progressi in medicina最新文献

Introduction: In recent times, TikTok 'weight loss influencers' have been promoting the use of GLP-1 receptor agonist drugs, with particular emphasis on semaglutide. The popularity of this class of drugs has been amplified by the statements of Elon Musk, who publicly declared in October 2022 that he had lost weight thanks to Wegovy, a semaglutide-based medication launched in the US. In Italy, GLP-1 receptor agonists are mainly indicated for the treatment of type 2 diabetes, but in certain cases they can be prescribed off-label for obesity and overweight. The aim of this study is to assess the impact of Elon Musk's statements on the use of semaglutide within Regional Health Service of the Lazio Region.

Methods: Dispensations of GLP-1 receptor agonist drugs (ATC: A10BJ) within Regional Health Service in the Lazio Region between January 2022 and March 2023 were analysed, identifying those related to semaglutide (ATC: A10BJ06). Monthly time series data on new users (with a 1-year washout period) of semaglutide and other GLP-1 drugs were compared to identify any changes after October 2022. In addition, the proportion of patients for whom it was possible to verify the indication of diabetes through health administrative data was examined.

Results: Analysis of the monthly trends for the entire class of GLP-1 receptor agonist drugs showed no difference in the monthly average of incident users between the pre and post Elon Musk statements. However, an increase in incident users was observed for semaglutide (monthly average: from 872 pre to 1,380 post) at the expense of the use of other drugs in the same class (monthly average: from 711 pre to 208 post). The proportion of semaglutide users for whom diabetes could not be confirmed remained stable over time at approximately 9.5%.

Conclusions: Elon Musk's statements seem to have had an impact on the use of semaglutide among patients in the Lazio region. Further analyses are necessary to carefully assess the presence of possible other factors influencing the preference for semaglutide over other GLP-1 receptor agonists.

The paper highlights the limited healthcare access for women in Rome's outskirts, worsened by gender-related barriers. The progressive reduction of services at the via Manfredonia clinic has left the Quarticciolo community underserved. To address this, Ambulatorio Popolare Roma Est promotes grassroots mobilization and conducted a survey identifying local women's health priorities, like cervical cancer screening, psychological counseling, and contraception. Findings underline the clinic's critical role, advocating for its revitalization and expanded outreach, including LGBTQ+ needs.

Aim of the study was to assess the use of pharmacological therapies provided in Nursing Homes and Protected Residences of the Umbria Region, with reference to central nervous system medications. In 2022, 200 ddd (defined daily doses) per 100 bed-days were administered in Umbria's long term care facilities, representing a 6.2% decrease compared to the previous year. Dermatological drugs had the highest consumption (35 ddd), followed by antihypertensives (26.5 ddd) and laxatives (15.6 ddd). Categories with the largest increases included antianemic preparations (+136%) and non-systemic antibiotics (+21%). Among Cns drugs, benzodiazepines and antipsychotics increased by 18% and 0.5 ddd respectively, while antidepressants decreased by 17.1%. In the setting of long-term care, a person-centered therapeutic approach should be considered to ensure the well-being of patients.

New Santa Chiara Hospital in Cisanello is under construction as part of Pisa University Hospital (Aoup). The 1000 beds and 5.000 employees Hospital (currently on two distant pavilion facilities) will find in 2026 a unique location in Cisanello, through the expansion of hospital buildings. The project aims structural and technological innovation and deep development of the organization. New responsibilities, new roles, new care delivery, organizational models and new logistics will be needed in new spaces. Our approach to change management is setting up future through bottom-up engagement and participation. In the meanwhile, we are working on a strong smart hospital design for buildings, users, care and hospital governance. New spaces are shared and care settings homogeneous, beyond our known borders: this is a cultural challenge we have been dealing with for two years. Currently, we are studying the corporate organizational culture and nursing care delivery model through research, engaging front-line nursing staff and nursing management, planning future organization and designing future hospital life. Smart Hospital Project involves analysis of needs in digitization, connection of processes and adoption of new tools that can allow better use of resources, increase patient safety and costs reduction. Research, change management and Smart Hospital are our change drivers. This can be replicated to other realities facing challenge like us, with resilient approach and shared construction of organizational change.